Assessment of Abuse Potential of Rapastinel in Humans

Brief Summary

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Intervention / Treatment

  • Drug: Rapastinel
  • Drug: Ketamine
  • Drug: Placebo

Condition or Disease

  • Human Abuse Potential

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 18 Years to 55 Years   (Adult)
Enrollment: 72 ()
Funded by: Industry

Masking

Clinical Trial Dates

Start date: Nov 01, 2018
Primary Completion: Mar 24, 2019
Completion Date: Mar 29, 2019
Study First Posted: Jan 10, 2019
Results First Posted: Aug 31, 2020
Last Updated: May 16, 2019

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 55

More Details

NCT Number: NCT03799900
Other IDs: RAP-PK-12
Study URL: https://ClinicalTrials.gov/show/NCT03799900
Last updated: Jan 27, 2021